As shown in Fig. 4q, patients with low ZMYND11/high HNRNPA1 expression exhibited significantly shorter biochemical recurrence- or metastasis-free survival compared to those with high ZMYND11/low HNRNPA1 expression, indicating a synergistic prognostic effect of both genes on prostate cancer severity. The gene discussed is ZMYND11; the disease is prostate carcinoma.